$2.12
+0.24 (+12.77%)
Open$2.07
Previous Close$1.88
Day High$2.42
Day Low$2.06
52W High$30.80
52W Low$1.89
Volume—
Avg Volume9.5K
Market Cap11.26M
P/E Ratio—
EPS$-5.27
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,813.7% upside
Current
$2.12
$2.12
Target
$40.57
$40.57
$36.99
$40.57 avg
$64.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.39M | 5.45M | 4.30M |
| Net Income | -1,299,864 | -1,279,500 | -760,803 |
| Profit Margin | -24.1% | -23.5% | -17.7% |
| EBITDA | -1,608,718 | -1,854,994 | -1,475,925 |
| Free Cash Flow | -1,268,218 | -1,023,573 | -724,682 |
| Rev Growth | -8.0% | -5.0% | +17.9% |
| Debt/Equity | 0.74 | 0.71 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |